Academic and Community Cancer Research United

A cancer research network conducting clinical trials that translate the latest

discoveries into new therapies for cancer treatment and symptom management


  Our Members

Our network includes more than 100 leading academic medical centers and community oncology practices in the United States and internationally.     Our members >

 Clinical Trials

ACCRU conducts industry-sponsored and investigator-initiated, phase II and III cancer treatment and symptom management trials across many types of cancer.     Clinical trials >


ACCRU offers a full range of clinical trial development and management services – from protocol development, to regulatory management, to data analysis and biorepository and correlative laboratory services.    Services >


ACCRU investigator Kathryn Ruddy, M.D., is a medical oncologist at Mayo Clinic’s campus in Rochester, Minnesota. She is currently the principal investigator for an ACCRU trial evaluating the benefit of immunotherapy to treat patient with triple negative breast cancer. 


“The ACCRU network offers the opportunity to test novel cancer therapies across multiple academic centers and community oncology practices. ACCRU is playing a critical role in helping to test a promising therapy for triple negative breast cancer, an aggressive disease that does not respond to current standard therapies.  This is an understudied area. We need more clinical trials and research to make strides in identifying effective treatments for these patients,” says Dr. Ruddy.


Dr. Ruddy co-chairs the Symptom Control/Survivorship Cross Disciplinary Group in the Mayo Clinic Cancer Center with Charles Loprinzi, M.D., vice chair of ACCRU. In this role, Dr. Ruddy helps coordinate all research and clinical efforts focused on improving survivorship care both during and after cancer treatment. In her clinical practice, Dr. Ruddy cares for patients with breast cancer.